Panacea Biotec Limited

Panacea Biotech Limited

Sukhjeet Singh

Rajesh Jain

Lavit Jambu

Kour Chand Jindal

Aniruddha Datta

Sampath Kumar Devarajan

The present invention relates to field of live attenuated recombinant tetravalent dengue vaccines and methods of producing stable compositions. Present invention specifically relates to a stable composition and methods of using such a stable composition comprising live attenuated recombinant dengue virus, stabilizer, bulking agent and optionally buffering agents, wherein the live attenuated dengue virus is generated from &#x394; 30 and or &#x394; 31 deleted or mutated dengue strains. More specifically, the present invention relates to stabilizers for freeze-dried live attenuated immunogenic and/or vaccine compositions that may comprise, inter alia, dengue virus(es). The invention further relates to stabilized, freeze-dried live attenuated immunogenic and/or vaccine compositions of, dengue virus(es), which may contain these stabilizers. Other aspects of the invention are described in or are evident from the following disclosure, and are within the ambit of the invention.

Stable live attenuated recombinant dengue vaccine

Extended release pharmaceutical compositions comprising mycophenolate sodium as the active agent, wherein the said composition exhibits a characteristic release profile when subjected to in-vitro dissolution study, and wherein said mycophenolate sodium is released in a sustained manner in-vivo for a prolonged duration in such quantities that substantially alleviates or at least reduces the chances of causing any associated gastrointestinal side effect(s) without compromising the bioavailability of the said active agent are provided. The present invention also provides process of preparing dosage form compositions and prophylactic and/or therapeutic methods of using such dosage form. The compositions of the present invention are useful for the management such as prophylaxis, amelioration and/or treatment of immunosuppressant indicated disease(s)/disorder(s) especially for the treatment or prevention of organ, tissue or cellular allograft or xenograft rejection, e.g. after transplant, or the management of immune-mediated diseases (autoimmune diseases).

Extended release compositions comprising mycophenolate sodium and processes thereof

The present invention relates to a combination vaccine comprising a mixture of antigens for protection against diseases such as diphtheria, tetanus, acellular pertussis, and infections caused byand polio viruses. The present invention also relates to inclusion of antigens for protection against infections caused Hepatitis virus and other pathogens, such that administration of the vaccine can simultaneously immunize a subject against more than one pathogen. The invention in particular relates to a fully liquid stable combination vaccine comprising the antigens as indicated above and the methods for manufacturing the same.

Combination vaccine with acellular pertussis

The invention relates to novel compositions comprising of an extract of the plant, particularly with pharmaceutically acceptable carrier(s)/base(s), optionally with additional therapeutic agent(s) useful for the treatment of anorectal disease and colonic diseases such as hemorrhoids, fissures, cracks, fistulas, abscesses, inflammatory bowel disease, and the like. The novel compositions possess properties to control inflammation, prevent capillary bleeding and fragility in mammalians, particularly human beings. Process for the preparation of such novel compositions comprising an extract of the plantand pharmaceutically acceptable carrier(s)/base(s) useful for the treatment of anorectal disease including hemorrhoids, and colonic diseases are also provided. The composition comprise of flavonoidal and phenolic constituents extracted from the plantthat possess anti-inflammatory, analgesic, haemostatic and wound-healing properties.

Growing community of inventors

New Delhi, India

Sukhjeet Singh